Objective
Brain cancers such as glioblastoma multiforme (GBM) are practically incurable due to their location, invasiveness and highly aggressive nature. The use of light-based treatments of GBM by activating tumor-localized photosensitizers, such as in photodynamic therapy (PDT) has been clinically evaluated, but with limited success. This is mainly due to the limited penetration of light into tissue and the efficient spread of tumor cells typically up to at least 2 cm from the resection margin. Moreover, the existing photon based treatments (photodynamic therapy) are highly invasive and usually require open-cranium surgery, due to the need for external light sources. In the Lumiblast project the photons are produced inside the tumor cells in the form of chemiluminescence avoiding the major limitation of using external light to treat solid, deep-sited and inaccessible tumors. The principle utilized in Lumiblast may also be relevant for cancers of other origins. Due to its nature Lumiblast is expected to act on individual cells, rather than the collective lesion; it could thus completely eliminate the hitherto incurable GBM. Each GBM cell is expected to become a small lamp providing the light required for the photosensitive agents to become activated, killing the tumour cells from the inside. Lumiblast requires a concerted interdisciplinary action. The project coordinator (Berg’s group, Oslo University Hospital, OUS) is world renowned in PDT and photomedicine, while the team from the University of Athens (Georgios Vougioukalakis’ group, UoA) is up and coming with high expertise in synthetic chemistry. The Polytechnic University of Valencia (Miguel Miranda’s group, UPV) team is headed by a world leader in Photochemistry, the University of Oslo partner (Hanne H. Tønnensen’s group, UiO) is specialized in pharmaceutical formulation, and Knight Scientific Ltd (KSL, CEO Jan Knight) is an SME with an impressive track record in ROS-activated luminescence. This 4.5-year project will establish the Lumiblast breakthrough technology by providing proof-of-concept in extracellular systems, GBM cell cultures and animal models, with the vision to advance Lumiblast to the clinic 5-6 years after the end of the proposed project.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences clinical medicine surgery
- natural sciences chemical sciences physical chemistry photochemistry
- medical and health sciences clinical medicine oncology
- social sciences economics and business business and management employment
- natural sciences physical sciences theoretical physics particle physics photons
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.2. - EXCELLENT SCIENCE - Future and Emerging Technologies (FET)
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.2.1. - FET Open
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
RIA - Research and Innovation action
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-FETOPEN-2014-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
0450 OSLO
Norway
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.